Slc18A2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SLC18A2 Gene is involved in biological pathways relevant to neurodegenerative diseases. It plays important roles in neuronal function, cellular signaling, ion transport, protein homeostasis, or stress response mechanisms.
Dysregulation or mutations in this gene contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders.
SLC18A2 encodes the vesicular monoamine transporter 2 (VMAT2), which is responsible for transporting neurotransmitters from the cytoplasm into synaptic vesicles. VMAT2 packages dopamine, norepinephrine, epinephrine, serotonin, and histamine into vesicles for regulated release during neurotransmission.[1]
VMAT2 is essential for maintaining neurotransmitter pools in presynaptic terminals and protecting cytosolic catecholamines from oxidative deamination by monoamine oxidase (MAO). It uses a proton gradient established by V-ATPase to drive vesicular uptake against concentration gradients.[2]
VMAT2 is a therapeutic target in Parkinson's disease. Tetrabenazine and valbenazine, VMAT2 inhibitors, are used to treat hyperkinetic movement disorders. Reduced VMAT2 expression has been observed in PD brains, contributing to dopaminergic dysfunction.[3]
Homozygous SLC18A2 mutations cause severe infantile-onset parkinsonism-dystonia (also known as THAP2 deficiency). This autosomal recessive disorder presents with early-onset movement abnormalities, developmental delay, and poor response to dopaminergic therapy.[4]
VMAT2 polymorphisms have been associated with susceptibility to various neuropsychiatric conditions including schizophrenia, bipolar disorder, and ADHD, reflecting its central role in monoaminergic neurotransmission.[5]
VMAT2 is expressed in monoaminergic neurons:
VMAT2 expression is a key marker for identifying monoaminergic neuron populations in the brain.[6]
The study of Slc18A2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Eiden LE, et al. Adv Pharmacol. 2004;48:109-136.
[2] Pettibone DJ, et al. Nat Rev Drug Discov. 2006;5(7):555-565.
[3] Lim KL, et al. Mol Neurobiol. 2015;52(1):458-469.
[4] Rilstone JJ, et al. Brain. 2013;136(Pt 2):483-493.
[5] Frey KA, et al. J Comp Neurol. 1997;378(3):388-402.